The improved financials are largely non-recurring due to the VOWST sale gains and cost cuts; traders should focus on upcoming Q2 2026 SER-155 data readout as a key catalyst for pipeline validation and potential partnership interest.
Price Chart
Executive Summary
Seres Therapeutics reported a net income of $5.7 million from continuing operations in 2025, a significant improvement from a $125.8 million loss in 2024, driven by lower operating expenses and $75 million in additional gains from installment payments related to the sale of VOWST to Nestlé. The company has $45.8 million in cash and expects to fund operations through Q3 2026, while advancing its pipeline including SER-155 and SER-603, with clinical data from an investigator-sponsored SER-155 trial expected in Q2 2026.
Key Financial Metrics
Key Facts
- Net income from continuing operations was $5.7 million in 2025 vs. $125.8 million net loss in 2024
- R&D expenses decreased to $49.1 million in 2025 from $64.6 million in 2024
- G&A expenses dropped to $39.2 million in 2025 from $53.2 million in 2024
- Cash and cash equivalents totaled $45.8 million as of December 31, 2025
- Company expects cash runway through Q3 2026
- Clinical data from investigator-sponsored SER-155 trial in irEC expected in Q2 2026
- SER-155 is Phase 2 ready for allo-HSCT but funding is pending
- No revenue from operations; $789K in grant revenue in 2025
Financial Impact
Improved net income by $131.5 million YoY due to lower expenses and $75M gain from VOWST sale installments, but core operations remain unprofitable with no product revenue
Risk Factors
- Cash runway ends in Q3 2026 with no clear path to profitability
- Heavy reliance on partnerships or additional financing to advance SER-155 and SER-603
- No product revenue; business model remains unproven post-VOWST divestiture
- Forward-looking statements dominate narrative with limited near-term commercial catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254451 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.98 | awaiting T+20 | — | $1.79 (+9.60%) |
Aug 24, 2026 9w ago | EFFECT | $4.66 $4.02 | ▲ +13.73% | ▲ +15.05% | $1.79 (+61.59%) |
Aug 5, 2026 11w ago | 8-K | $5.01 $5.54 | ▲ +10.69% | ▲ +11.29% | $1.79 (−64.24%) |
Jul 8, 2026 15w ago | 8-K | $7.14 $5.01 | ▼ −29.90% | ▼ −33.17% | $1.79 (−74.93%) |
Jun 5, 2026 20w ago | 8-K | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.79 (−73.00%) |
Jun 5, 2026 20w ago | Press Release | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.79 (−73.00%) |
May 19, 2026 22w ago | Insider Cluster | $7.66 $6.61 | ▼ −13.71% | ▼ −14.45% | $1.79 (−76.63%) |
May 5, 2026 25w ago | 8-K | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.79 (+76.13%) |
May 5, 2026 25w ago | Press Release | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.79 (+76.13%) |
May 4, 2026 25w ago | Press Release | $7.69 $7.64 | ▼ −0.65% | ▼ −6.30% | $1.79 (−76.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers